Skip to main content

CCTG Connection



Published:
Category: Other

We are sad to share that on June 16, 2023, Dr Walter Illarion Kocha (London, Ontario) has passed away.

Walter was an oncologist at the London Regional Cancer Centre for 34 years and the founder of their Neuroendocrine Program and one of pioneers of PRRT. Education and research were two of his great passions during his career, leading him to become both a foremost expert on treating neuroendocrine cancer, and a respected associate professor of Medicine and Oncology at Western University.

Read More



Published:
Category:
The Pharmacy Network looking for disease site reps
The Pharmacy Network has several volunteer opportunities available.
 
The network has openings for Disease Site Reps: Gastrointestinal, & Lung
If interested, please go to the Pharmacy Network webpage here: https://www.ctg.queensu.ca/private/pharm_net/
Read More

Published:
Category: Group updates
The deadline for an ID.me account with Multi-Factor Authentication is now TBD

The deadline to complete the identity verification and Multi-Factor Authentication (MFA) process through ID.me has changed from 1-JAN-2024 to "To Be Determined" and alternate options to meet the US government requirements are being explored.  Based on this new information, the CCTG network can hold implementation efforts at this time.

Read More

Published:
Category: Trials
Closed to Accrual: CO27
Please be advised that the CCTG CO27 Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-Risk Stage III Colon Cancer in Adjuvant Setting has closed to accrual having met the accrual target.
The primary objective for the study is 3 year Disease Free Survival (DFS) Secondary Objectives: 2 year DFS, Overall Survival, safety of study treatment.
 
For more information please visit the CCTG CO27 mem
Read More



Published:
Category: Group updates
Canada Day Long Weekend Closures

The CCTG Central Offices will operate with limited coverage on Friday, June 30 and will be closed on Monday July 3, 2023 for the Canada Day statutory holiday. Regular hours will resume July 4 at 8:30 am (EDT).

Read More

Published:
Category: Group updates
Trial-specific DSMC Summary Reports

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:

Read More

Published:
Category: Publications

Late-breaking results for the IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic pleural mesothelioma.

Read More

Published:
Category: Publications
Study results pave the way for a new standard of care for advanced-stage hodgkin lymphoma

A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Read More